|Bid||3.20 x 40700|
|Ask||3.32 x 34100|
|Day's Range||3.2700 - 3.4200|
|52 Week Range||2.6600 - 6.4000|
|Beta (3Y Monthly)||1.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2019 - Mar 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
A “trade war truce” was expected to come from the dinner between President Trump and Chinese President Xi Jinping over the weekend and that is what exactly happened. China and the United States agreed to a ceasefire in their bitter trade war on Saturday, including no escalated tariffs in Jan. Trump will leave tariffs on $200 billion worth of Chinese imports at 10 percent at the beginning of the new year. The Nasdaq Composite Index climbed 0.79 percent to close at 7,330.54.
HENDERSON, NV / ACCESSWIRE / November 19, 2018 / There are several biotech and cannabis companies in the news that could create profit opportunities for investors this week. Propanc Biopharma, Inc. (PPCB) ...
Opko Health (OPK) is focused on advancing multiple research and development (or R&D) programs including label expansion of Rayaldee and the development of novel therapies in 2018.
Wall Street analysts expect Opko Health to report selling, general, and administrative (or SG&A) expenses of $365.60 million in fiscal 2018, which would be a YoY decline of 29.83%. The company is expected to witness SG&A expenses of $437.64 million in fiscal 2019, which would be a YoY rise of 19.70%. Wall Street analysts also expect Opko Health to report SG&A expenses of $491.90 million in fiscal 2020, which would be a YoY rise of 12.40%.
In its third-quarter earnings conference call, Opko Health (OPK) forecasted its total product revenues to fall in the range of $28 million to $32 million in the fourth quarter. The company also reported Rayaldee sales of $5.8 million in the third quarter, which is a 21% rise on a sequential basis. Rayaldee witnessed a 222% YoY rise and an 18% sequential rise in prescription volumes in the third quarter.
Opko Health (OPK) is focused on advancing the penetration of its 4Kscore blood test. Opko Health has witnessed a 19% YoY rise in urologists performing 4Kscore blood tests in the 12 months ending September 2018. On May 18, Opko Health issued a press release announcing its plans to ensure Medicare coverage for the 4Kscore blood test despite the non-coverage policy proposed by Novitas Solutions.
In its third-quarter earnings conference call, Opko Health (OPK) forecasted that its revenues from services will fall in the range of $185 million to $205 million in the fourth quarter. Wall Street analysts expect Opko Health to report revenues of $1.04 billion in fiscal 2018, which would be a YoY decline of 2.59%. Wall Street analysts expect Opko Health to report revenues of $1.27 billion in fiscal 2020, which would be a YoY rise of 13.54%.
NEW YORK, NY / ACCESSWIRE / November 13, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against OPKO Health, Inc. ("OPKO" or the "Company) (OPK) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired OPKO securities between September 26, 2013 and September 7, 2018, both dates inclusive (the ''Class Period''). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
On November 9, Opko Health (OPK) closed at $3.09, which was 11.46% lower than its previous closing price. The stock was trading 15.57% lower than its closing price of $3.66 on November 1. To know more about the major events that had a significant impact on Opko Health’s stock price, read Why Opko Health Rose 15% Yesterday.
NEW YORK, NY / ACCESSWIRE / November 13, 2018 / OPKO Health was seeing big gains in Monday’s session on a stellar third quarter report. Shares of Exact Sciences Corp. were plummeting despite any remarkable ...
NEW YORK, Nov. 12, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against OPKO Health, Inc. (“OPKO” or “the Company”) (NASDAQ: OPK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between September 26, 2013 and September 7, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 13, 2018.